A New Approach to Assess Drug Development Performance

A. Rosiello, N. Dimitri, F. Fiorini

Research output: Contribution to journalArticlepeer-review


This article suggests that successful innovation in biopharmaceuticals is strongly related to the ability of firms to move compounds forward along the drug pipeline, relatively to other companies, within the same therapeutic area. We used this intuition to build indicators of performance at the firm-level and use them to conduct empirical analysis that relies upon a comprehensive database. We consider the effect of various factors on drug development performance, including R&D funds allocation across therapeutic areas and the proportion of biological molecules in the drug development portfolio. Subsequently, we show that a correlation exists between our performance variables and the per-capita growth of biopharmaceutical firms' revenues.
Original languageEnglish
Pages (from-to)420-427
JournalDrug Discovery Today
Issue number9-10
Early online date18 Jan 2013
Publication statusPublished - May 2013


Dive into the research topics of 'A New Approach to Assess Drug Development Performance'. Together they form a unique fingerprint.

Cite this